BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7877556)

  • 1. Pegaspargase for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
    [No Abstract]   [Full Text] [Related]  

  • 2. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-linked asparaginase marketed.
    Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical application of asparaginase activity levels following treatment with pegaspargase.
    Bleyer A; Asselin BL; Koontz SE; Hunger SP
    Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
    Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
    Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
    Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
    Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaspargase: a review of clinical studies.
    Graham ML
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
    Benitez L; Perissinotti AJ; Santarossa M; Marini BL
    Pediatr Blood Cancer; 2015 Jun; 62(6):1115. PubMed ID: 25649118
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
    Thomas X; Cannas G; Chelghoum Y; Gougounon A
    Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FDA approves new leukemia drug; expands use of current drug.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17338066
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
    Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
    Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
    Pediatr Blood Cancer; 2015 Jun; 62(6):1116. PubMed ID: 25732374
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?
    Pinheiro JP; Boos J
    Br J Haematol; 2004 Apr; 125(2):117-27. PubMed ID: 15059133
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
    Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
    Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
    [No Abstract]   [Full Text] [Related]  

  • 20. Asparaginases: where do we go from here?
    Ettinger LJ
    J Pediatr Hematol Oncol; 1999; 21(1):3-5. PubMed ID: 10029804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.